Puma Biotechnology (PBYI) Consolidated Net Income (2010 - 2026)
Puma Biotechnology (PBYI) posted Consolidated Net Income of -$3.8 million for Q1 2026, down 122.26% on a QoQ basis from $16.9 million in Q4 2025, and down 226.19% year-over-year from $3.0 million in Q1 2025.
Puma Biotechnology (PBYI) Consolidated Net Income (2010 - 2026) Analysis & Trends
Puma Biotechnology's Consolidated Net Income history runs 17 years deep, the most recent figure standing at -$3.8 million for Q1 2026.
- Quarterly Consolidated Net Income fell 226.19% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.8 million (up 265.22% YoY) and the FY2025 annual result came in at $34.5 million, up 19834.29% from the prior year.
- Consolidated Net Income was -$3.8 million for Q1 2026 at Puma Biotechnology, down from $16.9 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $20.3 million in Q3 2024 and bottomed at -$11.1 million in Q4 2024.
- A 5-year average of $3.1 million and a median of $2.1 million in 2023 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2023 — Consolidated Net Income surged 1710.0% — and 2024, when it sank 443.68%.
- Puma Biotechnology's Consolidated Net Income stood at -$5.2 million in 2022, then soared by 341.62% to $12.4 million in 2023, then slumped by 189.57% to -$11.1 million in 2024, then soared by 251.26% to $16.9 million in 2025, then slumped by 122.26% to -$3.8 million in 2026.
- Business Quant data shows PBYI's Consolidated Net Income at -$3.8 million in Q1 2026, $16.9 million in Q4 2025, and $8.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 469.79 Bn | 465.00 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.62 Bn | 62.62 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.18 Bn | 50.99 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Puma Biotechnology | 412.86 Mn | 374.58 Mn | 34.39 Mn | -3.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.75 Mn |
| Dec 31, 2025 | 16.86 Mn |
| Sep 30, 2025 | 8.84 Mn |
| Jun 30, 2025 | 5.86 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | -11.15 Mn |
| Sep 30, 2024 | 20.32 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | 12.45 Mn |
| Sep 30, 2023 | 5.80 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | -5.15 Mn |
| Sep 30, 2022 | -360,000.00 |
| Jun 30, 2022 | 9.37 Mn |
| Mar 31, 2022 | -3.40 Mn |
| Dec 31, 2021 | 4.22 Mn |
| Sep 30, 2021 | -44.67 Mn |
| Jun 30, 2021 | -5.11 Mn |